Relapsed malignant pleural mesothelioma: An impressive response to Nivolumab monotherapy

Pulmonology. 2022 Mar-Apr;28(2):142-144. doi: 10.1016/j.pulmoe.2021.10.002. Epub 2021 Nov 18.

Authors

S Costa-Martins¹, I Vicente², S Valente²

Affiliations

¹ Pulmonology Department, Centro Hospitalar Universitário Cova da Beira, Covilhã, Portugal. Electronic address: sara.m.costamartins@gmail.com.
² Pulmonology Department, Centro Hospitalar Universitário Cova da Beira, Covilhã, Portugal.

PMID: 34801435
DOI: 10.1016/j.pulmoe.2021.10.002

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents, Immunological* / adverse effects
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / pathology
Mesothelioma, Malignant*
Nivolumab / therapeutic use

Substances

Antineoplastic Agents, Immunological
Nivolumab